10-QPeriod: Q1 FY2024

QUEST DIAGNOSTICS INC Quarterly Report for Q1 Ended Mar 31, 2024

Filed April 24, 2024For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) reported its first quarter 2024 results, showing a modest increase in net revenues driven by its core Diagnostic Information Services (DIS) segment. Despite a slight overall revenue growth of 1.5% to $2.37 billion, operating income saw a marginal decline of 1.7% to $300 million, and net income attributable to Quest Diagnostics decreased by 3.9% to $194 million. This was reflected in diluted earnings per share, which fell to $1.72 from $1.78 in the prior year's comparable quarter. The company completed an acquisition of Lenco Diagnostic Laboratories for $111 million, contributing to the growth in its DIS segment, although overall revenue per requisition saw minimal change. Management highlighted the ongoing 'Invigorate' program aimed at driving cost savings and productivity improvements, which is being leveraged to offset inflationary pressures and reimbursement challenges. Looking ahead, Quest Diagnostics maintains a strong liquidity position with significant borrowing capacity available.

Financial Highlights

56 data points
Beta

Revenue

$2.37B

32.6% Gross Margin

Net Income

$194.00M

8.2% Net Margin

EPS (Diluted)

$1.72

Total Assets

$13.95B

Cash & Equivalents

$474.00M

Free Cash Flow

$50.00M

Financial Statements
Beta
Revenue$2.37B
Cost of Revenue$1.59B
Gross Profit$771.00M
SG&A Expenses$440.00M
Operating Expenses$2.07B
Operating Income$300.00M
Interest Expense$49.00M
Net Income$194.00M
EPS (Basic)$1.74
EPS (Diluted)$1.72
Shares Outstanding (Basic)111.00M
Shares Outstanding (Diluted)112.00M

Key Highlights

  • 1Net revenues increased by 1.5% to $2.37 billion for the three months ended March 31, 2024, compared to $2.33 billion in the prior year.
  • 2Operating income decreased by 1.7% to $300 million, and net income attributable to Quest Diagnostics declined by 3.9% to $194 million.
  • 3Diluted earnings per share (EPS) were $1.72, a decrease from $1.78 in the first quarter of 2023.
  • 4The company completed the acquisition of Lenco Diagnostic Laboratories for $111 million, adding to its Diagnostic Information Services (DIS) segment.
  • 5Cost of services increased by 2.3% to $1.595 billion, primarily due to higher supplies, wages, and benefit costs, partially offset by cost savings from the Invigorate program.
  • 6Net cash provided by operating activities significantly increased by $60 million to $154 million, driven by lower performance-based compensation payments and the timing of income tax payments.
  • 7Quest Diagnostics has $1.0 billion remaining under its share repurchase authorization and declared a quarterly cash dividend of $0.75 per common share.

Frequently Asked Questions

Quest Diagnostics reported a 1.5% increase in net revenues to $2.37 billion for the three months ended March 31, 2024, compared to $2.33 billion in the same period of 2023. The Diagnostic Information Services (DIS) segment, which represents over 95% of revenues, saw a 1.7% increase.

The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to offset inflationary pressures and reimbursement challenges. For the first quarter of 2024, the company incurred $17 million in pre-tax charges related to restructuring and integration activities, including employee separation costs, which are part of the ongoing efforts under this program.

Operating income decreased by 1.7% to $300 million, and net income attributable to Quest Diagnostics declined by 3.9% to $194 million. This resulted in diluted earnings per share falling to $1.72 from $1.78 in the prior year's first quarter.

Net cash provided by operating activities saw a substantial increase of $60 million to $154 million for the three months ended March 31, 2024, compared to the prior year. This improvement was attributed to lower performance-based compensation payments and the timing of income tax payments.